At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 125 enrolled
Drug / intervention
Ocriplasmin 25µg +3 moredrug
Likely dose
Ocriplasmin 25µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial
In Brief
A Phase 2 clinical trial evaluating Ocriplasmin 25µg, Ocriplasmin 75µg, and 2 other interventions for Vitrectomy. Completed, enrolled 125 participants across 20 sites.
Detailed Summary
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitrectomy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionOct 2008
TodayJul 2026
First PostedDec 19, 2006
Enrollment StartDec 1, 2006
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.5 years ago
Interventions
Ocriplasmin 25µgdrug
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
Ocriplasmin 75µgdrug
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
Ocriplasmin 125µgdrug
Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
Placebodrug
Intravitreal injection of placebo